Ann: NYR-BI03 Phase Ia Clinical Trial Update - Correction, page-50

  1. 1,224 Posts.
    lightbulb Created with Sketch. 157
    Coming from a poster that stated 4 months ago they won’t be in the clinic for next 10 years, don’t have any money, will be taken over for 1 cent and trolling the forum non stop. Great thing about you was the fact I collected 6.5 million shares at a garbage price and I thank you for that. Mate you can be as salty as you want.

    Do some research before posting. Three decades of research has already proven up one thing and that’s calcium influx reduction reduces primary and secondary brain injury. What 3 decades of data has de risked is the fact that glutamate antagonist like NA-1 failed not on half life because their 10 min half life had 5 hours of clinical treatment but failed because the conclusion that is now being understood in clinical setting that inhibiting glutamate in animals and humans was effective at at reducing brain injury but inhibiting glutamate also reduced the survival of neurons in the human brain but not animals.

    The past decade has been the study of TRPC channels and the only drug in the world in this drug class created to actually reach human trials and 6 years of safety and pre clinical success. GLP studies have given us an insight of what’s coming up in human studies for bioavailability and safety.

    ITS called investing and once safety is cleared, phase 2 will for the first time show a clinical response both for cardiovascular health and primary and secondary brain injury. But by then this would be a billion dollar plus company on a takeover. Hawk70 just to remind you it’s a 17 million market cap with 8 million in cash and 100 million dollar plus market cap is coming
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
22.0¢
Change
-0.025(10.2%)
Mkt cap ! $46.40M
Open High Low Value Volume
24.5¢ 25.0¢ 22.0¢ $256.0K 1.085M

Buyers (Bids)

No. Vol. Price($)
3 67420 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 25083 2
View Market Depth
Last trade - 16.10pm 24/06/2025 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.